How do we select an antipsychotic for those with schizophrenia?

References

• Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018 Jun;17(2):149–160.
   PubMed Web of Science ®Google Scholar
• Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015 Feb;29(2):97–115.
   PubMed Web of Science ®Google Scholar
• Vermeulen J, van Rooijen G, Doedens P, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017 Oct;47(13):2217–2228.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939–951.
   Google Scholar
• Grunder G, Heinze M, Cordes J, et al. NeSSy study group. effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry. 2016 Aug;3(8):717–729.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011 Feb;29(1):127,48,viii.
   Web of Science ®Google Scholar
• Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry Off J World Psychiatr Assoc WPA. 2018;17(3):330–340.
   PubMed Web of Science ®Google Scholar
• Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012 Aug;13(11):1545–1573.
   PubMed Web of Science ®Google Scholar
• Dold M, Tardy M, Samara MT, et al. Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. World J Biol Psychiatry. 2016 Apr;17(3):210–220.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019 Jun;18(2):208–224.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015 Jul;41(4):892–899.
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):625–639.
   PubMed Web of Science ®Google Scholar
• Nemeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 Mar 18;389(10074):1103–1113.
   PubMed Web of Science ®Google Scholar
• Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017 Mar 1;174(3):216–229.
   PubMed Web of Science ®Google Scholar
• Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014 Apr 24;9(4):e94112.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Y, Su Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017 Nov 21;17(1):373,017-1539-0.
   Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):3–8.
   PubMed Web of Science ®Google Scholar
• Gomez-Revuelta M, Pelayo-Teran JM, Juncal-Ruiz M, et al. Long-term antipsychotic effectiveness in first episode of psychosis: a 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol. 2018 Dec 1;21(12):1090–1101.
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24.
   PubMed Web of Science ®Google Scholar
• Gentile S. Discontinuation rates during long-term, second-generation antipsychotic long-acting injection treatment: a systematic review. Psychiatry Clin Neurosci. 2019 May;73(5):216–230.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li C, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017 Sep;27(9):835–844.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Krause M, Huhn M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017 Sep;4(9):694–705.
   PubMed Web of Science ®Google Scholar
• Grover S, Avasthi A. Clinical practice guidelines for the management of schizophrenia in children and adolescents. Indian J Psychiatry. 2019 Jan;61(Suppl 2):277–293.
   PubMedGoogle Scholar
• Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005 Mar 1;73(2–3):139–145.
   PubMed Web of Science ®Google Scholar
• Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019 Mar 7;45(2):315–329.
   PubMed Web of Science ®Google Scholar